A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).
Phase of Trial: Phase I/II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs LC 002 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2013 Results published in JAIDS.
- 22 May 2012 Actual patient number changed from 26 to 28 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History